Cer(d18:1/16:0)
|
Basic information |
| Metabolite name | Cer(d18:1/16:0) |
 | HMDB0004949 |
 |
C00195 |
 |
5283564 |
| Synonyms | N-palmitoyl-d-sphingosine; |
| No. of studies | 12 |
|
Basic information |
| Metabolite name | Cer(d18:1/16:0) |
| HMDB0004949 |
|
C00195 |
|
5283564 |
| Synonyms | N-palmitoyl-d-sphingosine; |
| No. of studies | 12 |
|
Relationship between Cer(d18:1/16:0) and depression (count: 12) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | Serum | ICR mouse | Up |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M1097 | Type2 | probiotic-treated depression group vs. placebo-treated depression group | Faece | Human | Down |
| Study M122 | Type3 | maprotiline group vs. control group | Prefrontal cortex | BALB/c mouse | Up |
| Study M207 | Type1 | depressed group vs. control group | Hippocampus | Kunming mouse | Down |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Down |
| Study M609 | Type2 | LPS + NBP group vs. LPS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M687 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M696 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M696 | Type2 | CUMS + liquiritin group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M696 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M970 | Type1 | MDD group vs. control group | Plasma | Human | Down |